

ERRATA

Univerzita Karlova, Farmaceutická fakulta v Hradci Králové

Katedra: Katedra farmakognozie a farmaceutické botaniky

Školitel: PharmDr. Daniela Hulcová, Ph.D.

Kandidát: Tereza Buchalová

Oprava: změna názvu Diplomové práce

Původní text:

Izolace alkaloidů z *Hippeastrum* cv. Ferrari a jejich biologická aktivita

Isolation of alkaloids from *Hippeastrum* cv. Ferrari and their biological activity

Oprava textu:

Izolace alkaloidů z *Hippeastrum* ferrari a jejich biologická aktivita

Isolation of alkaloids from *Hippeastrum* ferrari and their biological activity

Oprava: Změna názvu diplomové práce v Abstraktu (str. 69)

Původní text:

Název diplomové práce: Izolace alkaloidů z *Hippeastrum* cv. Ferrari a jejich biologická aktivita

Oprava textu:

Název diplomové práce: Izolace alkaloidů z *Hippeastrum* ferrari a jejich biologická aktivita

Oprava: Změna názvu diplomové práce v Abstract (str. 71)

Původní text:

Title of Thesis: Isolation of alkaloids from *Hippeastrum* cv. Ferrari and their biological activity

Oprava textu:

Title of Thesis: Isolation of alkaloids from *Hippeastrum* ferrari and their biological activity

Oprava: Změna klíčových slov (str.70)

Původní text:

Klíčová slova: *Hippeastrum* cv. Ferrari, Amaryllidaceae, alkaloidy, Alzheimerova choroba, biologická aktivita, acetylcholinesterasa, butyrylcholinesterasa, prolyl oligopeptidasa, cytotoxicita, antimalarická aktivita.

Oprava textu

Klíčová slova: *Hippeastrum* ferrari, cibule, alkaloidní extrakty, GC/MS analýza, biologická aktivita, acetylcholinesterasa, butyrylcholinesterasa.

Oprava: Změna anglických klíčových slov (str. 72)

Původní text:

Keywords: *Hippeastrum* cv. Ferrari, Amaryllidaceae, alkaloids, Alzheimer's disease, biological activity, acetylcholinesterase, butyrylcholinesterase, prolyl oligopeptidase, cytotoxicity, antimalarial activity.

Oprava textu

Keywords: *Hippeastrum* ferrari, Amaryllidaceae, biological activity, acetylcholinesterase, butyrylcholinesterase.

Oprava: Uvedení stránek v citacích (str. 73–77)

Původní text:

² Dalecká M., Havelek R., Královec K., Brůčková L., Cahlíková L.: Amaryllidaceae family alkaloids as potential drugs for cancer treatment. *Chemické Listy* 2013.

⁴ Dalecká M., Havelek R., Královec K., Brůčková L., Cahlíková L.: Alkaloidy rostlin čeledi Amaryllidaceae jako potenciální léčiva v terapii nádorových onemocnění. *Chemické Listy* 2013.

⁵ Ferdausi A., Chang X., Hall A., Jones M.: Galanthamine production in tissue culture and metabolomic study on Amaryllidaceae alkaloids in *Narcissus pseudonarcissus* cv. Carlton. *Industrial Crops and Products*.

⁶ Al Shammari L., Hulcová D., Maříková J., et al.: Amaryllidaceae alkaloids from *Hippeastrum X Hybridum* CV. Ferrari, and preparation of vittatine derivatives as potential ligands for Alzheimer's disease. *South African Journal of Botany*.

⁷ Atrahimovich D., Harris R., Eitan R., Cohen M., Khatib S.: Galantamine quantity and alkaloid profile in the bulbs of *Narcissus tazetta* and daffodil cultivars (Amaryllidaceae) grown in Israel. *Metabolites* 2021.

¹⁴ De Andrade J. P., Pigni N. B., Torras-Claveria L., et al.: Alkaloids from the *Hippeastrum* genus: Chemistry and biological activity. *Revista Latinoamericana de Quimica*.

- ¹⁶ Desgagné-Penix I.: Biosynthesis of alkaloids in Amaryllidaceae plants: a review. *Phytochemistry Reviews*. 2021.
- ¹⁷ Takos A. M., Rook F.: Towards a molecular understanding of the biosynthesis of Amaryllidaceae alkaloids in support of their expanding medical use. 2013.
- ¹⁸ Koutová D., Maafi N., Havelek R., et al. Chemical and Biological Aspects of Montanine-Type Alkaloids Isolated from Plants of the Amaryllidaceae Family. *Molecules*.
- ¹⁹ Jin Z., Yao G.: Amaryllidaceae and Sceletium alkaloids. *Natural Product Reports*. 2019.
- ²⁰ Nair J.J., Van Staden J.: The plant family Amaryllidaceae as a source of cytotoxic homolycorine alkaloid principles. *South African Journal of Botany*. 2021.
- ²¹ Šafratová M., Hostalková A., Hulcová D., et al.: Alkaloids from *Narcissus poeticus* cv. Pink Parasol of various structural types and their biological activity. *Archives of Pharmacal Research*. 2018.
- ²² Sung H., Ferlay J., Siegel R.L., et al.: Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*. 2021.
- ²³ Dumont P., Ingrassia L., Rouzeau S., et al.: The Amaryllidaceae isocarbostryril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. *Neoplasia*. 2007.
- ²⁴ Nair J.J., Van Staden J.: Cytotoxicity studies of lycorine alkaloids of the Amaryllidaceae. *Natural Product Communications*. 2014.
- ²⁵ Koutová D., Havelek R., Peterová E., et al.: Pancracine, a montanine-type amaryllidaceae alkaloid, inhibits proliferation of A549 lung adenocarcinoma cells and induces apoptotic cell death in molt-4 leukemic cells. *International Journal of Molecular Sciences*. 2021.
- ²⁶ Jin Y.H., Min J.S., Jeon S., et al.: Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections. *Phytomedicine*. 2021.
- ²⁷ Szilávik L., Gyuris Á., Minárovits J., Forgo P., Molnár J., Hohmann J.: Alkaloids from *Leucojum vernum* and antiretroviral activity of Amaryllidaceae alkaloids. *Planta Medica*. 2004.
- ²⁸ Likhitwitayawuid K., Angerhofer C. K., Chai H., Pezzuto J. M., Cordell G. A., Ruangrunsi N.: Cytotoxic and antimalarial alkaloids from the bulbs of *Crinum amabile*. *Journal of Natural Products*. 1993.
- ²⁹ Čahlíková L., Breiterová K., Opletal L.: Chemistry and biological activity of alkaloids from the genus *lycoris* (Amaryllidaceae). *Molecules*. 2020.
- ³⁰ Cheesman L., Nair J. J., Van Staden J.: Antibacterial activity of crinane alkaloids from *Boophone disticha* (Amaryllidaceae). *Journal of Ethnopharmacology*. 2012.
- ³² Ka S., Koirala M., Mérindol N., Desgagné-Penix I.: Biosynthesis and biological activities of newly discovered amaryllidaceae alkaloids. *Molecules* (Basel, Switzerland). 2020.
- ³³ Hulcová D., Maříková J., Korábečný J., et al.: Amaryllidaceae alkaloids from *Narcissus pseudonarcissus* L. cv. Dutch Master as potential drugs in treatment of Alzheimer's disease. *Phytochemistry*. 2019.
- ³⁴ Holmes C., Amin J.: Dementia. *Medicine* (United Kingdom). 2020.

- ³⁵ Gale S. A., Acar D., Daffner K. R.: Dementia. American Journal of Medicine. 2018.
- ³⁸ Sahyouni R., Verma A., William Chen J.: Alzheimer's Disease Decoded: The History, Present, and Future of Alzheimer's Disease and Dementia. World Scientific Publishing. 2017.
- ³⁹ Jack C. R., Lowe V. J., Weigand S. D., et al.: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: Implications for sequence of pathological events in Alzheimers disease. Brain. 2009.
- ⁴⁰ Zheng W. H., Bastianetto S., Mennicken F., Ma W., Kar S.: "Amyloid β peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures," Neuroscience. 2020.
- ⁴¹ Peng Y., Xing C., Xu S. et al: "L-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid- β peptide in rats," European Journal of Pharmacology. 2009.
- ⁴² Xian Y. F., Lin Z. X., Mao Q. Q., et al.: Bioassay-guided isolation of neuroprotective compounds from uncaria rhynchophylla against beta-amyloid-induced neurotoxicity. Evidence-based Complementary and Alternative Medicine. 2012.
- ⁴³ Farrer L.A., Cupples L.A., Haines J.L. et al: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA,1997.
- ⁴⁴ Arribas-Ayllon M.: The ethics of disclosing genetic diagnosis for Alzheimers disease: Do we need a new paradigm? British Medical Bulletin. 2011.
- ⁴⁵ Gustaw-Rothenberg K., Lerner A., Bonda D. J., et al.: Biomarkers in Alzheimers disease: Past, present and future. Biomarkers in Medicine. 2010.
- ⁴⁷ Levy K., Lanctôt K. L., Farber S. B., Li A., Herrmann N.: Does pharmacological treatment of neuropsychiatric symptoms in Alzheimers disease relieve caregiver burden? Drugs and Aging. 2012.
- ⁴⁹ Baron S., Ulstein I., Werheid K.: Psychosocial interventions in Alzheimer's disease and amnesic mild cognitive impairment: Evidence for gender bias in clinical trials. Aging and Mental Health. 2015.
- ⁵¹ Viña J., Lloret A.: Why women have more Alzheimer's disease than men: Gender and mitochondrial toxicity of amyloid- β peptide. Journal of Alzheimer's Disease. 2010.
- ⁵² McKhann G. M., Knopman D. S., Chertkow H., et al.: The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia. 2011.
- ⁵³ Folstein M. F., Folstein S. E., McHugh P. R.: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975.
- ⁵⁵ Tabet N.: Acetylcholinesterase inhibitors for Alzheimer's disease: Anti-inflammatories in acetylcholine clothing. Age and Ageing. 2006.
- ⁵⁶ Hausner L., Frölich L.: Antidementia Drug Therapy of Alzheimer's Dementia: Status 2018 and Outlook. Deutsche Medizinische Wochenschrift. 2019.
- ⁵⁷ Chen Y. D., Zhang J., Wang Y., Yuan J. L., Hu W. L.: Efficacy of cholinesterase inhibitors in vascular dementia: An updated meta-analysis. European Neurology. 2016.

⁵⁸ Loy C., Schneider L.: Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews. Published online 2006.

⁵⁹ McShane R., Westby M. J., Roberts E., et al.: Memantine for dementia. Cochrane Database of Systematic Reviews. 2019.

⁶¹ Mayer S. C., Kreft A. F., Harrison B., et al.: Discovery of begacestat, a Notch-1-sparing γ -secretase inhibitor for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry. 2008.

⁶² Stahl E.: Thin-Layer Chromatography: A Laboratory Handbook, 2.; Springer: Berlin, Heidelberg, New York, 1969.

⁶⁴ Hostalkova A., Marikova J., Opletal L., Korabecny J., Hulcova D., Kunes J., Novakova L., Perez D. I., Jun D., Kucera T., Andrisano V., Siatka T., Cahlikova, L.: Isoquinoline Alkaloids from *Berberis vulgaris* as Potential Lead Compounds for the Treatment of Alzheimer's Disease. Journal of Natural Products. 2019.

⁶⁵ Doskočil I., Hošťálková A., Šafratová M., Benešová N., Havlík J., Havelek R., Kuneš J., Královec K., Chlebek J., Cahlíková, L.: Cytotoxic Activities of Amaryllidaceae Alkaloids against Gastrointestinal Cancer Cells. Phytochemistry Letters, 2015.

⁶⁶ Havelek R., Muthna D., Tomsik P., Kralovec K., Seifrtova M., Cahlikova L., Hostalkova A., Safratova M., Perwein M., Cermakova E., et al: Anticancer Potential of Amaryllidaceae Alkaloids Evaluated by Screening with a Panel of Human Cells, Real-Time Cellular Analysis and Ehrlich Tumor-Bearing Mice. Chemico-Biological Interactions 2017.

⁶⁷ Ploemen I. H. J., Prudêncio M., Douradinha B. G., Ramesar J., Fonager J., Gemert G. J. van, Luty, A. J. F., Hermsen, C. C., Sauerwein, R. W., Baptista F. G., et al: Visualisation and Quantitative Analysis of the Rodent Malaria Liver Stage by Real Time Imaging. Plos one, 2009.

⁶⁸ Viladomat et al.: Alkaloids from *Brunsvigia josephinae*, 1994

⁶⁹ Via J., Arriortua M. I., Ochando L. E., Reventos M. M., Amigó J. M., Bastida J.: Structure of eugenine, an alkaloid from *Narcissus eugeniae*. Acta Crystallographica Section C, 1989.

Oprava textu

² Dalecká M., Havelek R., Královec K., et al.: Amaryllidaceae family alkaloids as potential drugs for cancer treatment. *Chemická Listy*, 107, 701–708, 2013.

⁴ Dalecká M., Havelek R., Královec K., et al.: Alkaloidy rostlin čeledi Amaryllidaceae jako potenciální léčiva v terapii nádorových onemocnění. *Chemické Listy* 107, 701–708, 2013.

⁵ Ferdousi A., Chang X., Hall A., et al.: Galanthamine production in tissue culture and metabolomic study on Amaryllidaceae alkaloids in *Narcissus pseudonarcissus* cv. Carlton. *Industrial Crops and Products* 144, 112058, 2020.

⁶ Al Shammari L., Hulcová D., Maříková J., et al.: Amaryllidaceae alkaloids from *Hippeastrum X Hybridum* CV. Ferrari, and preparation of vittatine derivatives as potential ligands for Alzheimer's disease. *South African Journal of Botany*, 136, 137–146, 2021.

⁷ Atrahimovich D., Harris R., Eitan R., et al.: Galantamine quantity and alkaloid profile in the bulbs of *Narcissus tazetta* and daffodil cultivars (Amaryllidaceae) grown in Israel. *Metabolites*, 11, 185. 2021.

- ¹⁴ De Andrade J. P., Pigni N. B., Torras-Claveria L., et al.: Alkaloids from the *Hippeastrum* genus: Chemistry and biological activity. *Revista Latinoamericana de Quimica*, *40*, 83-98, 2012.
- ¹⁶ Desgagné-Penix I.: Biosynthesis of alkaloids in Amaryllidaceae plants: a review. *Phytochemistry Reviews*, *20*, 409-431, 2021.
- ¹⁷ Takos A. M., Rook F.: Towards a molecular understanding of the biosynthesis of Amaryllidaceae alkaloids in support of their expanding medical use, *International Journal of molecular sciences*, *14*, 11713–11741, 2013.
- ¹⁸ Koutová D., Maafi N., Havelek R., et al: Chemical and Biological Aspects of Montanine-Type Alkaloids Isolated from Plants of the Amaryllidaceae Family. *Molecules*, *25*, 2337, 2020.
- ¹⁹ Jin Z., Yao G.: Amaryllidaceae and Sceletium alkaloids. *Natural Product Reports*, *33*, 1318–1343, 2016.
- ²⁰ Nair J.J., Van Staden J.: The plant family Amaryllidaceae as a source of cytotoxic homolycorine alkaloid principles. *South African Journal of Botany*, *136*, 157-174, 2021.
- ²¹ Šafratová M., Hostalková A., Hulcová D., et al.: Alkaloids from *Narcissus poeticus* cv. Pink Parasol of various structural types and their biological activity. *Archives of Pharmacal Research*, *41*, 208–218. 2018.
- ²² Sung H., Ferlay J., Siegel R.L., et al.: Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, *68*, 394-424, 2021.
- ²³ Dumont P., Ingrassia L., Rouzeau S., et al.: The Amaryllidaceae isocarbostryril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. *Neoplasia*, *9*, 766–776, 2007.
- ²⁴ Nair J.J., Van Staden J.: Cytotoxicity studies of lycorine alkaloids of the Amaryllidaceae. *Natural Product Communications*, *9*, 1193–1210, 2014.
- ²⁵ Koutová D., Havelek R., Peterová E., et al.: Pancracine, a montanine-type amaryllidaceae alkaloid, inhibits proliferation of A549 lung adenocarcinoma cells and induces apoptotic cell death in molt-4 leukemic cells. *International Journal of Molecular Sciences*, *22*, 7014, 2021.
- ²⁶ Jin Y.H., Min J.S., Jeon S., et al.: Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections. *Phytomedicine*, *86*, 153440, 2021.
- ²⁷ Szlávik L., Gyuris Á., Minárovits J., et al.: Alkaloids from *Leucojum vernum* and antiretroviral activity of Amaryllidaceae alkaloids. *Planta Medica*, *70*, 871–873, 2004.
- ²⁸ Likhitwitayawuid K., Angerhofer C. K., Chai H., et al.: Cytotoxic and antimalarial alkaloids from the bulbs of *Crinum amabile*. *Journal of Natural Products*, *56*, 1331–1338, 1993.
- ²⁹ Cahlíková L., Breiterová K., Opletal L.: Chemistry and biological activity of alkaloids from the genus *lycoris* (Amaryllidaceae). *Molecules*, *25*, 4797, 2020.
- ³⁰ Cheesman L., Nair J. J., Van Staden J.: Antibacterial activity of crinane alkaloids from *Boophone disticha* (Amaryllidaceae). *Journal of Ethnopharmacology*, *140*, 405–408. 2012.

- ³² Ka S., Koirala M., Mérindol N., et al.: Biosynthesis and biological activities of newly discovered amaryllidaceae alkaloids. *Molecules*, 25, 4901, 2020.
- ³³ Hulcová D., Maříková J., Korábečný J., et al.: Amaryllidaceae alkaloids from *Narcissus pseudonarcissus* L. cv. Dutch Master as potential drugs in treatment of Alzheimer's disease. *Phytochemistry*, 165, 112055, 2019.
- ³⁴ Holmes C., Amin J.: Dementia. *Medicine (United Kingdom)*, 44, 687–690, 2020.
- ³⁵ Gale S. A., Acar D., Daffner K. R.: Dementia. *American Journal of Medicine*, 131, 1161–1169, 2018.
- ³⁸ Sahyouni R., Verma A., William Chen J.: *Alzheimer's Disease Decoded: The History, Present, and Future of Alzheimer's Disease and Dementia*. 59–112, World Scientific Publishing. 2017.
- ³⁹ Jack C. R., Lowe V. J., Weigand S. D., et al.: Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: Implications for sequence of pathological events in Alzheimers disease. *Brain*, 132, 1355-1365, 2009.
- ⁴⁰ Zheng W. H., Bastianetto S., Mennicken F., et al.: Amyloid β peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures, *Neuroscience*, 115, 201–2011, 2020.
- ⁴¹ Peng Y., Xing C., Xu S. et al: L-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid- β peptide in rats. *European Journal of Pharmacology*, 621, 38–45. 2009.
- ⁴² Xian Y. F., Lin Z. X., Mao Q. Q., et al.: Bioassay-guided isolation of neuroprotective compounds from *Uncaria rhynchophylla* against beta-amyloid-induced neurotoxicity. *Evidence-based Complementary and Alternative Medicine*, 802625, 2012.
- ⁴³ Farrer L.A., Cupples L.A., Haines J.L. et al: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *Jama*, 1349–1356, 1997.
- ⁴⁴ Arribas-Ayllon M.: The ethics of disclosing genetic diagnosis for Alzheimers disease: Do we need a new paradigm? *British Medical Bulletin*, 100, 7–21, 2011.
- ⁴⁵ Gustaw-Rothenberg K., Lerner A., Bonda D. J., et al.: Biomarkers in Alzheimers disease: Past, present and future. *Biomarkers in Medicine*, 4, 15–26, 2010.
- ⁴⁷ Levy K., Lanctôt K. L., Farber S. B., et al.: Does pharmacological treatment of neuropsychiatric symptoms in Alzheimers disease relieve caregiver burden? *Drugs and Aging*, 29, 167–179, 2012.
- ⁴⁹ Baron S., Ulstein I., Werheid K.: Psychosocial interventions in Alzheimer's disease and amnestic mild cognitive impairment: Evidence for gender bias in clinical trials. *Aging and Mental Health*, 19, 290–305, 2015.
- ⁵¹ Viña J., Lloret A.: Why women have more Alzheimer's disease than men: Gender and mitochondrial toxicity of amyloid- β peptide. *Journal of Alzheimer's Disease*, 20, 527–533, 2010.
- ⁵² McKhann G. M., Knopman D. S., Chertkow H., et al.: The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's and Dementia*, 7, 263–269, 2011.
- ⁵³ Folstein M. F., Folstein S. E., McHugh P. R.: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *Journal of Psychiatric Research*, 12, 189–198, 1975.

- ⁵⁵ Tabet N.: Acetylcholinesterase inhibitors for Alzheimer's disease: Anti-inflammatories in acetylcholine clothing. *Age and Ageing*, 35, 336–338, 2006.
- ⁵⁶ Hausner L., Frölich L.: Antidementia Drug Therapy of Alzheimer's Dementia: Status 2018 and Outlook. *Deutsche Medizinische Wochenschrift*, 144, 156–160, 2019.
- ⁵⁷ Chen Y. D., Zhang J., Wang Y., et al.: Efficacy of cholinesterase inhibitors in vascular dementia: An updated meta-analysis. *European Neurology*, 75, 132–141, 2016.
- ⁵⁸ Loy C., Schneider L.: Galantamine for Alzheimer's disease and mild cognitive impairment. *Cochrane Database of Systematic Reviews*, 1, 2006.
- ⁵⁹ McShane R., Westby M. J., Roberts E., et al.: Memantine for dementia. *Cochrane Database of Systematic Reviews*, 3, 2019.
- ⁶¹ Mayer S. C., Kreft A. F., Harrison B., et al.: Discovery of begacestat, a Notch-1-sparing γ -secretase inhibitor for the treatment of Alzheimer's disease. *Journal of Medicinal Chemistry*, 51, 7348–7351. 2008.
- ⁶² Stahl E.: *Thin-Layer Chromatography: A Laboratory Handbook*, 2.; 359, Springer: Berlin, Heidelberg, New York, 1969.
- ⁶⁴ Hostalkova A., Marikova J., Opletal L., et al.: Isoquinoline Alkaloids from *Berberis vulgaris* as Potential Lead Compounds for the Treatment of Alzheimer's Disease. *Journal of Natural Products*, 82, 239-248, 2019.
- ⁶⁵ Doskočil I., Hošťálková A., Šafratová M., et al.: Cytotoxic Activities of Amaryllidaceae Alkaloids against Gastrointestinal Cancer Cells. *Phytochemistry Letters*, 13, 394–398, 2015.
- ⁶⁶ Havelek R., Muthna D., Tomsik P., et al: Anticancer Potential of Amaryllidaceae Alkaloids Evaluated by Screening with a Panel of Human Cells, Real-Time Cellular Analysis and Ehrlich Tumor-Bearing Mice. *Chemico-Biological Interactions*, 275, 121–132, 2017.
- ⁶⁷ Ploemen I. H. J., Prudêncio M., Douradinha B. G., et al.: Visualisation and Quantitative Analysis of the Rodent Malaria Liver Stage by Real Time Imaging. *Plos one*, 4, e7881, 2009.
- ⁶⁸ Viladomat, F., Bastida, J., Codina, et al.: Alkaloids from *Brunsvigia josephinæ*, *Phytochemistry*, 35, 809–812, 1994.
- ⁶⁹ Via J., Arriortua M. I., Ochando L. E., et al.: Structure of eugenine, an alkaloid from *Narcissus eugeniae*. *Acta Crystallographica Section C*, 45, 2020–2022, 1989.